From: Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy
Therapy | Total N = 4,156 n (%) |
---|---|
Patients on monotherapy (% of total) | 3,188 (76.7) |
Number of patients by type of antipsychotic monotherapy (% of monotherapy) | |
Risperidone | 765 (24.0) |
Aripiprazole | 536 (16.8) |
Olanzapine | 505 (15.8) |
Quetiapine | 437 (13.7) |
Ziprasidone | 261 (8.2) |
Clozapine | 200 (6.3) |
Other second-generation antipsychotic | 57 (1.8) |
First-generation antipsychotic | 427 (13.4) |
Total on polypharmacy (% of total) | 968 (23.3) |
Number of patients by type of antipsychotic polypharmacy combinations (% of polypharmacy) | |
Combinations with first-generation antipsychotics | 257 (26.5) |
Combinations with olanzapine | 216 (22.3) |
Combinations with risperidone | 210 (21.7) |
Combinations with other second-generation antipsychotics | 186 (19.2) |
Combinations with clozapine | 99 (10.2) |
Top 5 polypharmacy combinations | |
Quetiapine and risperidone | 96 (9.9) |
Quetiapine and aripiprazole | 94 (9.7) |
Quetiapine and first-generation antipsychotic | 83 (8.6) |
Aripiprazole and risperidone | 65 (6.7) |
Aripiprazole and olanzapine | 65 (6.7) |